PAR fundamentals
PARADIGM BIOPHARMACEUTICALS LIMITED.. financial statements, including revenue, expenses, and profit
The total revenue of PAR for the last semiannual is 16.70 k AUD, and it's 74.62% lower compared to the previous semiannual. The net income of H1 25 is -5.92 M AUD.
H2 '17
H1 '18
H2 '18
H1 '19
H2 '19
H1 '20
H2 '20
H1 '21
H2 '21
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
−51.00 M
−34.00 M
−17.00 M
0.00
17.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: AUD
H2 '17
Jun 2017
H1 '18
Dec 2017
H2 '18
Jun 2018
H1 '19
Dec 2018
H2 '19
Jun 2019
H1 '20
Dec 2019
H2 '20
Jun 2020
H1 '21
Dec 2020
H2 '21
Jun 2021
H1 '22
Dec 2021
H2 '22
Jun 2022
H1 '23
Dec 2022
H2 '23
Jun 2023
H1 '24
Dec 2023
H2 '24
Jun 2024
H1 '25
Dec 2024
TTM
Gross profitYoY growth
−46.17 K
+65.92%
−73.40 K
+7.74%
−16.53 K
+64.21%
−73.49 K
−0.12%
−90.01 K
Operating incomeYoY growth
−26.92 M
−36.27%
−49.89 M
−54.49%
−14.60 M
+45.77%
−6.18 M
+87.61%
−20.78 M
Pretax incomeYoY growth
−26.31 M
−114.51%
−50.02 M
−53.23%
−14.68 M
+44.20%
−6.26 M
+87.49%
−20.94 M
Net incomeYoY growth
−20.04 M
−63.42%
−48.96 M
−53.63%
−9.69 M
+51.63%
−5.92 M
+87.90%
−15.62 M
−20.04 M
−48.96 M
−9.69 M
−5.92 M
−15.62 M
Basic earnings per share (Basic EPS)YoY growth
−0.07
−35.95%
−0.16
−41.88%
−0.03
+59.97%
−0.02
+89.77%
−0.04
Diluted earnings per share (Diluted EPS)YoY growth
−0.07
−35.95%
−0.16
−41.88%
−0.03
+59.97%
−0.02
+89.77%
−0.04
EBITDAYoY growth
−26.84 M
−36.55%
−49.82 M
−54.63%
−14.53 M
+45.89%
−6.11 M
+87.74%
−20.64 M
EBITYoY growth
−26.92 M
−36.27%
−49.89 M
−54.49%
−14.60 M
+45.77%
−6.18 M
+87.61%
−20.78 M